CLL-SLL/MTT Episode 1 - What You MUST Know About the Emerging Standard of Care for 1L Treatment of CLL and SLL

Enroll in this course

Estimated Time
0.50 hr

Release Date
Dec 01, 2022

Expiration Date
Dec 14, 2023

ACTIVITY DESCRIPTION 
The treatment landscape in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has shifted with the advent of novel targeted agents that are more tolerable than traditional chemoimmunotherapy. However, keeping up with the latest clinical evidence and updates to the clinical guidelines on these agents can be challenging for busy clinicians and their care teams. In this first episode of the 3-part educational series First-line Treatment of CLL/SLL: New Data and Practical Strategies for Practice Improvement, sit in on a conversation with our expert faculty as they discuss the new standard of care for CLL and SLL and how to apply this care transition to your patients and clinic.

 

Speakers

Sanjay K. Juneja

Sanjay K. Juneja, MD

Hematology, Medical Oncology
Chief of Oncology Line
Baton Rouge General  Hospital
Mary Bird Perkins Cancer Center
Baton Rouge, LA

Dr. Sanjay Juneja is a triple board certified Hematologist & Medical Oncologist serving as Chief of Oncology Service at Baton Rouge General Hospital, and a social & news media personality known as 'TheOncDoc' with over half a million followers. He is an active participant for the White House Healthcare Leaders in Social Media Roundtable and national speaker. Dr. Juneja is the host of an innovative podcast called 'Target: Cancer' with distinguished academicians and celebrities around the country, and been featured in several articles including The Washington Post and guested on dozens of acclaimed podcasts and regional news channels (PBS, CBS, NBC, NPR). He is a Business Report's 40 under 40 recipient from his hometown of Baton Rouge, where he partners with the LA Department of Health and Mayor's office to optimize healthcare access and outreach. Dr. Juneja currently practices in his beloved hometown of Baton Rouge Louisiana with his wife Dr. Lauren and their three wild boys.

Nicole Lamanna

Nicole Lamanna, MD

Associate Attending, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, NY
 

Nicole Lamanna, MD, serves as an Associate Professor of Medicine and Director of the Chronic Lymphocytic Leukemia (CLL) Program on the Leukemia Service for the Hematologic Malignancies Section in the Hematology/Oncology Division at Columbia University Medical Center. Dr. Lamanna specializes in the treatment of adult patients with acute and chronic leukemias. Her clinical research focus has been the development of novel combination therapies that include chemo-immunotherapy, immune-modulatory drugs, kinase inhibitors, bcl-2 inhibitors, and monoclonal antibodies. She is a staunch patient advocate and participates regularly in CLL patient advocacy groups with the goal of educating patients about their disease and treatment options. She has lectured and chaired CLL sessions at international and national meetings and has published in various scientific journals, including Blood, Journal of Clinical Oncology, Lancet and The New England Journal of Medicine.

Raajit K. Rampal

Raajit K. Rampal, MD, PhD

Associate Attending Physician 
Leukemia Service                   
Memorial Sloan Kettering Cancer Center   
New York, NY

Raajit K. Rampal, MD, PhD, is an Associate Member at Memorial Sloan-Kettering Cancer. The focus of his laboratory and clinical research has been to elucidate the mechanism of pathogenesis of the Philadelphia-chromosome negative Myeloproliferative Neoplasms (MPN) and to develop novel mechanism-based therapeutic approaches for MPNs.

Accreditation and Disclosure Information

TARGET AUDIENCE
This CE activity is intended for hematologic oncology clinicians including physicians, fellows, nurse practitioners, nurses, physician associates, and pharmacists who provide care for individuals with CLL and SLL.

EDUCATIONAL OBJECTIVES
After completing this CE activity, the participant should be better able to:
  • Incorporate guideline recommendations and real-world evidence supporting the emerging standard of care in practice
  • Evaluate emerging data regarding the mechanism of action and long-term safety and efficacy of recommended agents and combinations
ACCREDITATION, SUPPORT AND CREDIT
In support of improving patient care, Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
 
 
 
Physician Continuing Medical Education
Medical Learning Institute, Inc. (MLI) designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 0.5 contact hour and 0.5 contact hour in the area of pharmacology.
 
Continuing Pharmacy Education
Medical Learning Institute, Inc. designates this continuing education activity for 0.5 contact hour (0.05 CEU) of the Accreditation Council for Pharmacy Education.
 
Universal Activity Number: JA0007322-0000-22-122-H01-P
Type of Activity: Knowledge 
 
AAPA Credit Designation Statement

Medical Learning Institute, Inc. has been authorize by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until December 14, 2023. PAs should only claim credit commensurate with the extent of their participation.

 
Interprofessional Continuing Education (IPCE) Statement
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.
 
 
 
SUPPORT STATMENT
Supported by educational grants from Genentech, a member of the Roche Group and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
 
DISCLOSURE & CONFLICT OF INTEREST POLICY
Medical Learning Institute, Inc., is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education.  To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
 
FACULTY DISCLOSURES
Planner/Presenter
Sanjay Juneja, MD                        
Hematology, Medical Oncology
Chief of Oncology Line
Baton Rouge General  Hospital
Mary Bird Perkins Cancer Center
Baton Rouge, LA
 
Advisory Board/Consultant: Daiichi Sankyo and Guardant 360
Speakers’ Bureau:  AstraZeneca Pharmaceuticals, Daiichi Sankyo, Guardant 360, Merck & Co., Inc. and Tempus
Stock Ownership: Phenomune and xCures
Independent Contractor: xCures
 
Planner/Presenter
Nicole Lamanna, MD
Associate Attending, Leukemia Service
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, NY
 
Advisory Board/Consultant: AbbVie, AstraZeneca, BeiGene, Eli Lilly/Loxo, Genentech, Janssen, and Pharmacyclics
Research Grant: AbbVie, AstraZeneca, BeiGene, Eli Lilly/Loxo, Genentech, Octapharma, Oncternal Therapeutics, MingSight, and TG Therapeutics
 
Planner/Presenter
Raajit K. Rampal, MD, PhD
Associate Attending Physician
Leukemia Service                  
Memorial Sloan Kettering Cancer Center  
New York, NY
 
Advisory Board/Consultant for: AbbVie, Blueprint Medicines, Celgene/Bristol Myers Squibb, Constellation, CTI BioPharma, Disc Medicine, Galecto, Incyte, Novartis, Pharmaessentia, Promedior, Servier, Sierra Oncology/GlaxoSmithKline, Stemline, and Sumitomo Dainippon
Research Grant for: Constellation, Incyte, Ryvu, Stemline, Zentalis
 
All of the relevant financial relationships of individuals for this activity have been mitigated.
 
PLANNING COMMITTEE AND CONTENT/PEER REVIEWERS
The planners and content/peer reviewers from Medical Learning Institute, Inc., do not have any relevant financial relationship(s) to disclose with ineligible companies.
 
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 
METHOD OF PARTICIPATION
There are no fees for participating in or receiving credit for this CE activity. In order to receive credit, learners must participate in the entire CE activity, complete the post-test and activity evaluation form and your certificate of credit will be generated. A passing score of 70% or higher is needed to obtain credit.
 
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
 
If you have questions regarding your certificate, please contact Mary Vu via email at mvu@mlieducation.org
 
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days post-activity and will report your participation to the NABP only if you provide your NABP e-Profile number and DOB (MM/DD). Within 6 weeks, you can view your participation record at the NABP website: https://nabp.pharmacy/.
 
ABOUT THIS ACTIVITY
Medical Learning Institute, Inc. is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute, Inc. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute, Inc. or any of its partners, providers, and/or supporters
 
Copyright © 2022 Medical Learning Institute, Inc. All Rights Reserved.

Resources

Enroll in this course